RHOF and acute myeloid leukemia: Moreover, a subgroup analysis of the TCGA database (Acute Myeloid Leukemia, NEJM 2013) 24 indicated that the upregulation of RhoF in AML was a risk factor for reduced 1-year (median 12.0 vs. 9.2 months, P =0.001, Figure 5C), 3-year (median 24.6 vs. 9.2 months, P=0.001, Figure 5D), and 5-year (median 24.6 vs. 9.2 months, P=0.001, Figure 5E) OS in AML patients.